10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2018 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 26, 2019) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Operating Activities: | |||
| Net income | $ 5,460 | 4,644 | 13,488 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation expense | 226 | 233 | 177 |
| Amortization expense | 1,203 | 1,053 | 981 |
| Stock-based compensation expense | 845 | 638 | 380 |
| Deferred income taxes | 289 | (82) | (119) |
| In-process research and development impairment | 820 | 0 | 432 |
| Inventory reserve for excess raw materials | 440 | 0 | 0 |
| Other | 56 | 304 | 162 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | 480 | 754 | 1,192 |
| Inventories | (310) | (253) | (488) |
| Prepaid expenses and other | 903 | 358 | (520) |
| Accounts payable | (39) | (430) | 47 |
| Income taxes payable | (1,459) | 5,497 | 1,010 |
| Accrued liabilities | (514) | (818) | 305 |
| Net cash provided by operating activities | 8,400 | 11,898 | 17,047 |
| Investing Activities: | |||
| Purchases of marketable securities | (10,233) | (23,314) | (25,619) |
| Proceeds from sales of marketable securities | 1,522 | 10,440 | 13,039 |
| Proceeds from maturities of marketable securities | 24,336 | 7,821 | 1,700 |
| Other investments | (346) | 0 | (357) |
| Acquisitions, net of cash acquired | 0 | (10,426) | 0 |
| Capital expenditures | (924) | (590) | (748) |
| Net cash provided by (used in) investing activities | 14,355 | (16,069) | (11,985) |
| Financing Activities: | |||
| Proceeds from debt financing, net of issuance costs | 0 | 8,985 | 5,293 |
| Proceeds from convertible note hedges | 0 | 0 | 956 |
| Proceeds from issuances of common stock | 289 | 234 | 208 |
| Repurchases of common stock | (2,900) | (954) | (11,001) |
| Repayments of debt and other obligations | (6,250) | (1,811) | (1,981) |
| Payments to settle warrants | 0 | 0 | (469) |
| Payment of dividends | (2,971) | (2,731) | (2,455) |
| Other | (486) | (330) | (276) |
| Net cash provided by (used in) financing activities | (12,318) | 3,393 | (9,725) |
| Effect of exchange rate changes on cash and cash equivalents | (85) | 137 | 41 |
| Net change in cash and cash equivalents | 10,352 | (641) | (4,622) |
| Cash and cash equivalents at beginning of period | 7,588 | 8,229 | |
| Cash and cash equivalents at end of period | 17,940 | 7,588 | 8,229 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid, net of amounts capitalized | 1,070 | 1,038 | 885 |
| Income taxes paid | 3,198 | 3,342 | 2,436 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2018 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |